REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

26/06/2023 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230626:nRSZ9472Da&default-theme=true

RNS Number : 9472D  Venture Life Group PLC  26 June 2023

26 June 2023

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Director Dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, announces
that Carl Dempsey, Non-Executive Director, today purchased 100,000 ordinary
shares of 0.3p each in the Company ("Ordinary Shares") at a price of 38.00
pence per Ordinary Share.

Following this purchase, Mr Dempsey beneficially holds 148,500 Ordinary Shares
representing 0.12 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

 Venture Life Group PLC                                                        +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Broker)                                      +44 (0) 20 7397 8900
 Stephen Keys / Camilla Hume
 Russell Kerr / Michael Johnson (Sales)

 Singer Capital Markets (Joint Broker)                                         +44 (0) 20 7496 3000

 Shaun Dobson / Alaina Wong  (Corporate Finance)

 Jonathan Dighe (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, The Netherlands and Italy,
the Group's product portfolio includes some key products such as the UltraDEX
and Dentyl oral care product ranges, food supplements for maintaining brain
function, medical devices for women's intimate healthcare, fungal infections
and proctology, and dermo-cosmetics for addressing the signs of ageing.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands, these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

Through its Development & Manufacturing business in Italy, Biokosmes, the
Group also provides development and manufacturing services to companies for
consumer healthcare products, primarily medical devices.

 

 

The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Carl Dempsey

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Purchase of ordinary shares

 c)   Price(s) and volume(s)                                       100,000 ordinary shares at 38.00 pence per share

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      26 June 2023

 f)   Place of the transaction                                     London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSERDIRFIV